Thinking about the diagnosis and treatment of moyamoya disease under the epidemic of coronavirus disease 2019
10.3760/cma.j.issn.1673-4165.2020.05.002
- VernacularTitle:2019冠状病毒病疫情下烟雾病诊疗思考
- Author:
Zhengshan ZHANG
1
;
Zhengxing ZOU
;
Fangbin HAO
;
Lian DUAN
Author Information
1. 解放军总医院第五医学中心神经外科，北京 100071
- From:
International Journal of Cerebrovascular Diseases
2020;28(5):326-329
- CountryChina
- Language:Chinese
-
Abstract:
Coronavirus disease 2019 (COVID-19), caused by the 2019 novel coronavirus (2019-nCoV), is spreading on a large scale in China. COVID-19 mainly affects the respiratory system and cause symptoms such as severe hypoxemia and high fever. At present, there is no specific treatment drug, and patients' autoimmunity is closely related to disease prognosis. The brain tissue of patients with moyamoya disease is in a state of ischemia and hypoxia for a long time. Hypoxemia and high fever will aggravate the cerebral ischemia and hypoxia in patients with moyamoya disease, and patients with moyamoya disease may also have autoimmune abnormalities. Because people with moyamoya disease are also likely to have COVID-19 and COVID-19 can cause many conditions that may aggravate the symptoms of patients with moyamoya disease, which brings new problems and challenges to the clinical diagnosis and treatment of moyamoya disease. In this article, the diagnosis and treatment process and prevention and control measures of patients with moyamoya disease under the current epidemic situation are thought, and the key issues in the treatment of patients with moyamoya disease after suffering from COVID-19 are sorted out. It is hoped to provide reference for the diagnosis and treatment of moyamoya disease under the COVID-19 epidemic situation.
